GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (FRA:ICY) » Definitions » Accounts Payable & Accrued Expense for Financial Companies

Incyte (FRA:ICY) Accounts Payable & Accrued Expense for Financial Companies


View and export this data going back to 1993. Start your Free Trial

What is Incyte Accounts Payable & Accrued Expense for Financial Companies?

Accounts Payable & Accrued Expense for Financial Companies only applies to insurance companies.


Incyte (FRA:ICY) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (FRA:ICY) » Definitions » Accounts Payable & Accrued Expense for Financial Companies
Traded in Other Exchanges
Address
1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.